Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve

BMC Cardiovascular Disorders

Volumn 17, Issue 1, 2017, Pages

  Holmager, Pernille ^a,b   Egstrup, Michael ^c   Gustafsson, Ida ^d   Schou, Morten ^a,b   Dahl, Jordi S ^e   Rasmussen, Lars Melholt ^e   Møller, Jacob E ^e   Tuxen, Christian ^f   Faber, Jens ^a,b   Kistorp, Caroline ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Diabetes; Fibulin 1; Galectin 3; Left ventricular contractile reserve; Myocardial fibrosis

Indexed keywords

FIBULIN; FIBULIN 1; GALECTIN 3; UNCLASSIFIED DRUG; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; DOBUTAMINE; GALECTIN-3, HUMAN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; CELL TRANSFORMATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SYSTOLIC HEART FAILURE; BLOOD; CARDIAC MUSCLE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; FIBROSIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; STRESS ECHOCARDIOGRAPHY; UPREGULATION; VERY ELDERLY;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD GLUCOSE; CALCIUM-BINDING PROTEINS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DOBUTAMINE; ECHOCARDIOGRAPHY, STRESS; FEMALE; FIBROSIS; GALECTIN 3; GLUCOSE TOLERANCE TEST; HEART FAILURE, SYSTOLIC; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 85008507504     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-016-0437-6     Document Type: Article

References (27)

1. Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771-7.
2. Egstrup M, Schou M, Gustafsson I, et al. Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis. Eur J Heart Fail. 2011;13(3):319-26.
3. Egstrup M, Kistorp CN, Schou M, et al. Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure. Eur Heart J Cardiovasc Imaging. 2013;14(4):349-57.
4. Williams MJ, Odabashian J, Lauer MS, et al. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol. 1996;27(1):132-9.
5. Otasevic P, Popovic ZB, Vasiljevic JD, et al. Relation of myocardial histomorphometric features and left ventricular contractile reserve assessed by high-dose dobutamine stress echocardiography in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2005;7(1):49-56.
6. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121-8.
7. Jin QH, Lou YF, Li TL, et al. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med J (Engl). 2013;126(11):2109-15.
8. Gopal DM, Kommineni M, Ayalon N et al. Relationship of plasma galectin-3 to renal fuinction in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or abscence of heart failure. J Am Heart Assoc. 2012;1(5):e000760. doi: 10.1161/JAHA.112.000760. Epub 2012 Oct 25.
9. Beisvag V, Lehre PK, Midelfart H, et al. Aetiology-sepcific patterns in end-stage heart failure patients identified by functional annotation and classification of microarray data. Eur J Heart Fail. 2006;8:381-9.
10. Hansen ML, Dahl JS, Argraves WS, et al. Aortic valve stenosis and atrial fibrillation influence plasma fibulin-1 levels in patients treated with coronary bypass surgery. Cardiology. 2013;126(3):202-6.
11. Schoze A, Bladbjerg EM, Sidelmann Jj et al. Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes. Cardiovascl. Diabetol 2013 Jan 7;12:6. Doi: 10.1186/1475-2840-12-6
12. Dahl JS, Moller JE, Videbaek L, et al. Plasma fibulin-1 is linked to restrictive filling of the left ventricle and to mortality in patients with aortic valve stenosis. J Am Heart Assoc. 2012;1(6):e003889.
13. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79-108.
14. Christenson RH, Duh SH, Wu AH, et al. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem. 2010;43(7-8):683-90.
15. Cangemi C, Skov V, Poulsen MK, et al. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem. 2011;57(11):1556-65.
16. Argraves WS, Tran H, Burgess WH, et al. Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. J Cell Biol. 1990;111(6 Pt 2):3155-64.
17. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108(3):385-90.
18. Weigert J, Neumeier M, Wanninger J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010;95(3):1404-11.
19. Skov V, Cangemi C, Gram J, et al. Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes. Diabetes Care. 2014;37(3):760-6.
20. Hansen ML, Rasmussen LM. Associations between plasma fibulin-1, pulse wave velocity and diabetes in patients with coronary heart disease. J Diabetes Complications. 2015;29(3):362-6. doi: 10.1016/j.jdiacomp.2015.01.003. Epub 2015 Jan 13.
21. Paapstel K, Zilmer M, Eha J, et al. Association between fibulin-1 and aortic augmentation index in male patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2016;51(1):76-82. doi: 10.1016/j.ejvs.2015.09.004. Epub 2015 Oct 21.
22. Skov V, Knudsen S, Olesen M, et al. Global gene expression profiling displays a network of dysregulated genes in non-atherosclerotic arterial tissue from patients with type 2 diabetes. Cardiovasc Diabetol. 2012;11:15.
23. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60(14):1249-56.
24. Mewton N, Liu CY, Croisille P, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891-903.
25. Karamitsos TD, Francis JM, Myerson S, et al. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54(15):1407-24.
26. Singsaas EG, Manhenke CA, Dickstein K, et al. Circulation Galectin-3 levels are increased in patients with ischemic heart disease, but are not influenced by acute myocardial infarction. Cardiology. 2016;134:398-405. doi: 10.1159/000445103.
27. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010;12(8):826-32.